One study found that applying Vemurafenib to a xenograft model of BC cells (MDA-MB-231) revealed that Vemurafenib treatment resulted in downregulation of PI3K-AKT signaling (19), which may be responsible for the downregulation of BCL2A1 expression after Vemurafenib. Here, AKT1 is linked to breast cancer.